Clinical predictor of survival following docetaxel-based chemotherapy
暂无分享,去创建一个
Wen-Jeng Wu | Y. Chou | Shu-Pin Huang | Chun‐Nung Huang | Yung-Chin Lee | Hsiang-Ying Lee | Mei-Hui Lee | Kai-Fu Yang | Chun‐Hsiung Huang
[1] T. Inagaki,et al. Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer , 2013, International Journal of Clinical Oncology.
[2] K. Harada,et al. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. , 2013, Urologic oncology.
[3] Y. Pu,et al. Using age‐referenced prostate‐specific antigen percentile to predict survival outcomes in screened Taiwanese men , 2013, International journal of cancer.
[4] W. Berry,et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. , 2012, European urology.
[5] Yang Yao,et al. Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials , 2011, Journal of Cancer Research and Clinical Oncology.
[6] Ming-Tsang Wu,et al. Impact of prostate‐specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen‐deprivation therapy , 2011, The Prostate.
[7] R. Nemoto,et al. Interstitial pneumonitis induced by bicalutamide given for prostate cancer , 2011, International Journal of Clinical Oncology.
[8] T. H. van der Kwast,et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.
[9] Y. Sumiyoshi,et al. Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience. , 2010, Japanese journal of clinical oncology.
[10] Dae-Ho Lee,et al. Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. , 2010, Cancer research and treatment : official journal of Korean Cancer Association.
[11] K. Yamaguchi,et al. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone‐refractory prostate cancer , 2009, International journal of urology : official journal of the Japanese Urological Association.
[12] P. Johnston,et al. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer , 2008, British Journal of Cancer.
[13] R de Crevoisier,et al. The postchemotherapy PSA surge syndrome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] H. Akaza,et al. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. , 2008, Japanese journal of clinical oncology.
[15] P. Olbert,et al. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel , 2006, Anti-cancer drugs.
[16] I. Tannock,et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.
[17] C. Tangen,et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.
[18] X. Yao,et al. Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. , 2013, Asian journal of andrology.
[19] W. Ajiki,et al. Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. , 2011, Japanese journal of clinical oncology.
[20] T. H. van der Kwast,et al. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. , 2011, Actas urologicas espanolas.
[21] Mottet Nicolas,et al. 前立腺癌に関するEAUガイドライン パートII:進行性再発性および性腺摘除抵抗性前立腺癌の治療 , 2011 .
[22] K. Nakagawa,et al. Docetaxel in combination with prednisolone for hormone refractory prostate cancer. , 2010, Japanese journal of clinical oncology.
[23] T. Klatte,et al. Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy , 2007, International Urology and Nephrology.
[24] T. Redman. The Impact of , 1998 .